In this study we evaluated the antitumor activity of the allosteric mTORC1 inhibitor, rapamycin and of the ATP-competitive mTOR inhibitor WYE-354 on preclinical xenograft GBC tumor models. This evidence concerns the gene MTOR and neoplasm.